Mizuho on Sage Therapeutics (SAGE): 'management sounded very upbeat about the Zurzuvae launch, which could bode well for 1Q24 results'
Tweet Send to a Friend
Mizuho analyst Vamil Divan reiterated a Neutral rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
